Funder
Burroughs Wellcome Fund
National Center for Advancing Translational Sciences
American Cancer Society
American Association for Cancer Research
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference139 articles.
1. Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S. Unsuccessful trial of gene replacement in arginase deficiency. Zeitschrift für Kinderheilkunde. 1975;119:1–3.
2. Maguire AM, Russell S, Wellman JA, Chung DC, Yu Z-F, Tillman A, et al. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation–associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology. 2019;126:1273–85. https://doi.org/10.1016/j.ophtha.2019.06.017.
3. ClinicalTrials.gov [Internet]. Identifier NCT03399448, NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells). 2018 Jan 16. Available from: https://clinicaltrials.gov/ct2/show/NCT03399448?term=03399448&draw=2&rank=1.
4. Reardon S. CRISPR gene-editing creates wave of exotic model organisms. Nature. 2019;568:441–2.
5. Reardon S. Welcome to the CRISPR zoo. Nature. 2016;531:160–3. https://doi.org/10.1038/531160a.
Cited by
66 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献